Breaking News Instant updates and real-time market news.

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

, LZB

La-Z-Boy

$31.25

0.1 (0.32%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40

On The Fly: After Hours Movers

HIGHER: Maxim Integrated (MXIM), up 0.25% after it said in a regulatory filing that, last week, it named Sumeet Gagneja to serve as its principal accounting officer. DOWN AFTER EARNINGS: La-Z-Boy (LZB), down 13.8%... Cree (CREE), down 8%... 21Vianet (VNET), down 6.1%... Salesforce.com (CRM), down 1%. ALSO LOWER: root9B Holdings (RTNB), down 47.7% after it said it secured incremental funding of $500,000 to allow the company to meet its payroll obligations and said that there is no change in the foreclosure proceedings... Ultragenyx (RARE), down 10.1% after it said it plans to discontinue further clinical development of Ace-ER.

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

LZB

La-Z-Boy

$31.25

0.1 (0.32%)

CREE

Cree

$23.03

0.46 (2.04%)

VNET

21Vianet

$4.58

0.03 (0.66%)

CRM

Salesforce

$92.95

1.19 (1.30%)

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

RARE

Ultragenyx

$58.85

1.94 (3.41%)

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 23

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

  • 16

    Nov

MXIM Maxim Integrated
$44.39

0.68 (1.56%)

07/21/17
DBAB
07/21/17
NO CHANGE
Target $50
DBAB
Buy
Maxim Integrated weakness a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Ross Seymore views near-term weakness in shares of Maxim Integrated following the company's Q4 results as a buying opportunity. Weaker than expected sales in Q4 and guidance "will overwhelm" any positive takes on the company's "impressive" margins, Seymore tells investors in a research note. The analyst likes the stock's risk/reward and keeps a Buy rating on the name with a $50 price target.
06/15/17
RAJA
06/15/17
INITIATION
RAJA
Market Perform
Maxim Integrated resumed with a Market Perform at Raymond James
Raymond James analyst Chris Caso resumed coverage on Maxim with a Market Perform citing valuation.
04/21/17
EVER
04/21/17
DOWNGRADE
Target $46
EVER
In Line
Maxim Integrated downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst C.J. Muse downgraded Maxim Integrated saying the diversification/margin story is largely complete and shares are near his $46 price target. Muse sees modest headwinds ahead including slowing China BMS business and lack of Apple exposure in 2H and recommends moving to the sidelines.
04/21/17
LOOP
04/21/17
NO CHANGE
Target $51
LOOP
Buy
Maxim auto worries 'much ado about nothing,' says Loop Capital
Loop Capital analyst Betsy Van Hees attributes the after-hours weakness in Maxim Integrated shares despite the company's strong Q3 report and Q4 guidance to concerns over auto market commentary that may have been misinterpreted. After following up with management, she confirmed they were not making a broad sector call and she views concerns over a flat sequential guide in automotive as "much ado about nothing." Van Hees reiterates her Buy rating and $51 price target on Maxim shares.
LZB La-Z-Boy
$31.25

0.1 (0.32%)

02/23/17
02/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. NVIDIA (NVDA) downgraded to Underperform from Market Perform at BMO Capital and to Reduce from Buy at Nomura. 2. L Brands (LB) downgraded to Neutral from Overweight at Atlantic Equities. 3. FLIR Systems (FLIR) downgraded to In-Line from Outperform at Imperial Capital with analyst Jeff Kessler citing valuation following the recent rally in the shares. The analyst maintains a $38 price target for the stock. 4. La-Z-Boy (LZB) downgraded to Hold from Buy at Stifel with analyst John Baugh saying the company's January quarter results show that it is having difficulty generating organic growth. The analyst adds that "the furniture business remains challenged." 5. Dorman Products (DORM) downgraded to Market Perform from Outperform at FBR Capital with analyst Christopher Van Horn citing valuation. The analyst raised his price target for the shares to $80 from $68. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/23/17
STFL
02/23/17
DOWNGRADE
STFL
Hold
La-Z-Boy downgraded on results, sectior weakness at Stifel
Stifel analyst John Baugh downgraded La-Z-Boy, as he says that the company's January quarter results show that it is having difficulty generating organic growth. The analyst adds that "the furniture business remains challenged." Target to $30 from $33.
08/01/17
SIDC
08/01/17
DOWNGRADE
SIDC
Neutral
La-Z-Boy downgraded to Neutral from Buy at Sidoti
Sidoti analyst Anthony Lebiedzinski downgraded La-Z-Boy to Neutral due to shares approaching his $36 price target.
08/01/17
08/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. MGM Resorts (MGM) downgraded to Neutral from Buy at UBS with analyst Robin Farley saying the current valuation, with the shares up 37% over the past 12 months, now captures much of the value of the REIT transaction and improving Las Vegas outlook. 2. Boardwalk Pipeline (BWP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Elvira Scotto saying she expects the stock to be "range bound" until its 2019-2020 outlook become clearer. 3. La-Z-Boy (LZB) downgraded to Neutral from Buy at Sidoti with analyst Anthony Lebiedzinski saying shares are approaching his $36 price target. 4. Regeneron (REGN) downgraded to Underperform from Neutral at Baird with analyst Brian Skorney saying Dupixent expectations have gotten ahead of themselves and consensus numbers currently reflect an overlap with Cosentyx sales which looks like an overestimate. 5. Corporate Office Properties (OFC) downgraded to Sell from Hold at Stifel with analyst John Guinee saying he believes that the Real Estate Investment Trust will be hurt by "persistently weak leasing economics," the expirations of a large number of its leases with high rents, and efforts by defense and IT organization to keep rent costs low. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CREE Cree
$23.03

0.46 (2.04%)

04/27/17
ROTH
04/27/17
NO CHANGE
Target $27
ROTH
Buy
Cree price target lowered to $27 from $33 at Roth Capital
Roth Capital analyst Craig Irwin lowered his price target for Cree to $27 from $33 on valuation. Nonetheless, the analyst believes that with a smaller miss than peers coming from the weak January and transitory driver issues, weakness is overdone. That being said, the turnaround in Lighting Products is taking longer than anyone would like, he adds. Irwin reiterates a Buy rating on the shares.
05/22/17
05/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Neutral at JPMorgan with analyst Rod Hall saying while more negative news from the Apple (AAPL) royalty suit is likely, "material fundamental upside" exists from the closure of the NXP Semiconductors (NXPI) by the end of this year. The analyst views the deal as highly accretive. Hall also believes Apple ultimately will want to preserve its commercial relationship with Qualcomm. 2. Motorola Solutions (MSI) upgraded to Outperform from Market Perform at Raymond James with analyst Tavis McCourt saying shares look increasingly attractive based on improved demand visibility that is less economically sensitive than many of its peers, and demand catalysts from FirstNet buildouts that are expected to start in 2018. 3. Entegris (ENTG) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Toshiya Hari citing the recent pullback in shares and maintained a $29 price target. 4. Blackstone (BX) upgraded to Buy from Neutral at Citi with analyst William Katz saying the company's intentions to raise a $40B infrastructure fund should be a "valuation catalyst." 5. Cree (CREE) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he thinks that the company's new CEO could make positive changes at the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/20/17
ROTH
06/20/17
NO CHANGE
Target $29
ROTH
Buy
Wolfspeed's potential future value to Cree underappreciated, says Roth Capital
Roth Capital analyst Craig Irwin estimates that the Wolfspeed segment could drive $2.4B-$3.1B in value for Cree over the next eight years, which implies a current value of $12-$17 per share, though he argues that is currently being underappreciated by the market. Irwin, who keeps a Buy rating on Cree, raised his price target on the shares to $29 from $27.
05/22/17
JMPS
05/22/17
UPGRADE
JMPS
Outperform
Cree upgraded to Outperform from Market Perform at JMP Securities
JMP Securities analyst Joseph Osha upgraded Cree as he indicates that he thinks that the company's new CEO could make positive changes at the company. Target $29.
VNET 21Vianet
$4.58

0.03 (0.66%)

05/22/17
MSCO
05/22/17
NO CHANGE
MSCO
21Vianet named a long Research Tactical Idea at Morgan Stanley (pre-open)
CRM Salesforce
$92.95

1.19 (1.30%)

08/18/17
RBCM
08/18/17
NO CHANGE
RBCM
Salesforce billings growth can beat expectations, says RBC Capital
RBC Capital analyst Ross MacMillan believes that Salesforce's Q2 billings growth will beat expectations, and he preidtcs that it will raise its full-year revenue growth guidance. The analyst is upbeat on the company's fundamentals and keeps an Outperform rating.
08/21/17
RHCO
08/21/17
NO CHANGE
RHCO
Salesforce Q2 results likely to beat expectations, says SunTrust
SunTrust analyst Terry Tillman expects Salesforce's Q2 results to beat expectations "based on well-balanced growth across (its) Sales, Service, Marketing and Platform businesses." Tillman thinks that the company will perform well in 2H18 due to seasonal billings strength, a number of "Event driven catalysts" including its Dreamforce conference, and the increased monetization of its "newer cloud products." He expects the company's fiscal 2019 results to significantly beat expectations and expects the stock to perform well in the second half of this year. He keeps a $110 price target and a Buy rating on the shares.
08/22/17
BTIG
08/22/17
NO CHANGE
BTIG
Salesforce Q2 results likely to beat expectations, says BTIG
BTIG analyst Joel Fishbein, Jr says his checks with Salesforce's partners have convinced him that the company's Q2 results will beat expectations. The analyst says checks indicate that the company has a strong pipeline and stable pricing, and is benefiting from more "multi-cloud deployments and deeper penetration of the installed base." The analyst says the all of the company's "segments continue to show strength," while its ARPU continues to rise. He keeps a $100 price target and a Buy rating on the shares.
08/22/17
ROTH
08/22/17
NO CHANGE
Target $112
ROTH
Buy
Salesforce price target raised to $112 from $103 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Salesforce to $112 from $103 saying earnings comparisons are set to improve materially in Q2 and 2H18. The analyst reiterates a Buy rating on the shares.
RTNB root9B Technologies
$2.98

1.72 (136.51%)

RARE Ultragenyx
$58.85

1.94 (3.41%)

05/05/17
LEER
05/05/17
NO CHANGE
Target $89
LEER
Outperform
Ultragenyx price target lowered to $89 from $93 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Ultragenyx to $89 from $93 as he delays launch assumptions for triheptanoin programs to 2020 from 2019. Nonetheless, the analyst notes that the company announced pre-specified fracture healing data in X-linked hypophosphatemia patients who were enrolled in the recent Phase 3 study, which suggest burosumab is disease-modifying and correlates biomarker improvements to physiological benefit. He continues to assign 90% probability of success to burosumab, and reiterates an Outperform rating on the shares.
07/27/17
BERN
07/27/17
INITIATION
BERN
Market Perform
Ultragenyx initiated with a Market Perform at Bernstein
Bernstein analyst Vincent Chen started coverage of Ultragenyx with a $72 price target and a Market Perform rating. The analyst views the stock as fully valued.
07/27/17
07/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kinder Morgan (KMI) initiated with a Neutral at Mizuho. 2. Alpine Immune Sciences (ALPN) initiated with a Buy at Ladenburg. 3. Synaptics (SYNA) resumed with an Outperform at Cowen. 4. BioMarin (BMRN) and Ultragenyx (RARE) were initiated with a Market Perform at Bernstein. 5. Keane Group (FRAC) and ProPetro Holding (PUMP) were initiated with an Overweight at Capital One. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/17
EVER
08/16/17
INITIATION
Target $63
EVER
In Line
Ultragenyx initiated with an In Line at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Ultragenyx with an In Line and a $63 price target.

TODAY'S FREE FLY STORIES

NUVA

NuVasive

$51.99

-1.34 (-2.51%)

20:43
01/16/18
01/16
20:43
01/16/18
20:43
Downgrade
NuVasive rating change at Wells Fargo »

NuVasive downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

20:38
01/16/18
01/16
20:38
01/16/18
20:38
Recommendations
Juno Therapeutics, Celgene, Acquired by GILD 9/17, Gilead analyst commentary at Citi »

Juno could be worth $110…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

KITE

Acquired by GILD 9/17

GILD

Gilead

$80.25

1.23 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 12

    Feb

  • 16

    Feb

  • 25

    Mar

SNP

Sinopec

$83.07

-1 (-1.19%)

20:35
01/16/18
01/16
20:35
01/16/18
20:35
Upgrade
Sinopec rating change at Jefferies »

Sinopec upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

20:34
01/16/18
01/16
20:34
01/16/18
20:34
Downgrade
Shell Midstream rating change at Stifel »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

UNH

UnitedHealth

$232.90

4.26 (1.86%)

20:31
01/16/18
01/16
20:31
01/16/18
20:31
Recommendations
UnitedHealth analyst commentary at Piper Jaffray »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

AVXS

AveXis

$105.01

-12.49 (-10.63%)

20:31
01/16/18
01/16
20:31
01/16/18
20:31
Syndicate
AveXis 3.921M share Secondary priced at $102.00 »

Goldman Sachs, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OZRK

Bank of the Ozarks

$52.23

-0.24 (-0.46%)

20:26
01/16/18
01/16
20:26
01/16/18
20:26
Downgrade
Bank of the Ozarks rating change at Keefe Bruyette »

Bank of the Ozarks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 30

    Jan

WP

Worldpay

$78.26

0.66 (0.85%)

, VNTV

Symbol changed to WP

20:25
01/16/18
01/16
20:25
01/16/18
20:25
Initiation
Worldpay, Symbol changed to WP initiated at Goldman Sachs »

Worldpay reinstated with…

WP

Worldpay

$78.26

0.66 (0.85%)

VNTV

Symbol changed to WP

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.24

0.05 (0.16%)

, GS

Goldman Sachs

$258.46

1.43 (0.56%)

20:25
01/16/18
01/16
20:25
01/16/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$31.24

0.05 (0.16%)

GS

Goldman Sachs

$258.46

1.43 (0.56%)

USB

U.S. Bancorp

$57.17

0.19 (0.33%)

FAST

Fastenal

$55.44

-0.15 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

  • 15

    Feb

C

Citi

$77.11

0.27 (0.35%)

20:20
01/16/18
01/16
20:20
01/16/18
20:20
Downgrade
Citi rating change at Keefe Bruyette »

Citi downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 18

    Jan

  • 24

    Jan

O

Realty Income

$52.94

0.22 (0.42%)

19:12
01/16/18
01/16
19:12
01/16/18
19:12
Hot Stocks
Realty Income raises monthly dividend to 21.9c per share from 21.25c »

Realty Income announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:05
01/16/18
01/16
19:05
01/16/18
19:05
Hot Stocks
New Gold sees FY18 gold production 525,000-595,000 ounces »

Sees FY18 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:04
01/16/18
01/16
19:04
01/16/18
19:04
Hot Stocks
New Gold reports Q4 gold production 154,446 ounces »

Reports Q4 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:04
01/16/18
01/16
19:04
01/16/18
19:04
Hot Stocks
New Gold reports FY17 gold production 430,864 ounces »

Reports FY17 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$80.42

-0.12 (-0.15%)

18:50
01/16/18
01/16
18:50
01/16/18
18:50
Earnings
PayPal sees FY18 revenue $15B-$15.25B, consensus $15.35B »

Backs FY18 TPV Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

CE

Celanese

$109.67

-1.67 (-1.50%)

18:32
01/16/18
01/16
18:32
01/16/18
18:32
Hot Stocks
Celanese increases the price of low density polyethylene to 4c »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

RIG

Transocean

$11.47

-0.73 (-5.98%)

18:27
01/16/18
01/16
18:27
01/16/18
18:27
Hot Stocks
Transocean shareholders show 'overwhelming support' for Songa transaction »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

WMT

Walmart

$100.69

-0.18 (-0.18%)

18:13
01/16/18
01/16
18:13
01/16/18
18:13
Periodicals
Wal-Mart COO to be named international CEO, Reuters says »

Wal-Mart Stores COO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CME

CME Group

$152.20

-0.53 (-0.35%)

18:05
01/16/18
01/16
18:05
01/16/18
18:05
Hot Stocks
CME reaches daily trading volume record for Henry Hub Nat Gas futures on Jan 12 »

CME Group announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 01

    Feb

CE

Celanese

$109.67

-1.67 (-1.50%)

18:02
01/16/18
01/16
18:02
01/16/18
18:02
Hot Stocks
Celanese announces price increases for engineered materials polymer products »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SRC

Spirit Realty

$8.07

-0.03 (-0.37%)

17:46
01/16/18
01/16
17:46
01/16/18
17:46
Hot Stocks
Spirit Realty funds $35M into Shopko master lease »

Spirit Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

17:45
01/16/18
01/16
17:45
01/16/18
17:45
Conference/Events
Nutanix management to meet with Piper Jaffray »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

17:41
01/16/18
01/16
17:41
01/16/18
17:41
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Juno Therapeutics…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

NEWA

Newater Technology

$15.80

2.8 (21.54%)

VRS

Verso

$17.00

0.06 (0.35%)

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

IPSEY

Ipsen

RNST

Renasant

$43.86

0.15 (0.34%)

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

CSX

CSX

$58.13

-1.12 (-1.89%)

ATEN

A10 Networks

$7.31

-0.27 (-3.56%)

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

HIVE

Aerohive

$5.70

-0.19 (-3.23%)

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

XON

Intrexon

$13.77

-0.94 (-6.39%)

BOOT

Boot Barn

$19.10

-0.15 (-0.78%)

F

Ford

$13.10

-0.13 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 26

    Feb

  • 01

    Mar

  • 25

    Mar

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

NRZ

New Residential

$17.63

-0.11 (-0.62%)

17:35
01/16/18
01/16
17:35
01/16/18
17:35
Earnings
Breaking Earnings news story on New Residential »

New Residential sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

17:30
01/16/18
01/16
17:30
01/16/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Exelixis »

Exelixis up 3.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.